August 30, 2012 08:15 ET

Equity Research on Forest Laboratories Inc. and Teva Pharmaceutical Industries Ltd. - Drug Manufacturers Look to Profit From Branded and Generic Mix

NEW YORK, NY--(Marketwire - Aug 30, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Other industry and are offering free analytical research on Forest Laboratories Inc. (NYSE: FRX) and Teva Pharmaceutical Industries Limited (NYSE: TEVA). Register with us now to have free access to these research reports. Simply click on the link below.

Patent cliffs have certainly taken their toll on a number of drug manufacturing companies. However, a recent move by branded drug companies to enter the generic market has allowed them to recoup some of their losses. Several companies have also been offering coupons for their branded products that bring down costs. Get your free reports on Forest Laboratories Inc. and Teva Pharmaceutical Industries Limited at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Forest Laboratories Inc. and Teva Pharmaceutical Industries Limited then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.

Strong pipelines and FDA approval are also important for the industry and companies such as Forest Laboratories Inc. and Teva Pharmaceutical Industries Limited. Teva recently stated that its new drug application for its oral contraceptive candidate, Quartette, was accepted by the FDA. Company news on the generics front has also been positive, as Teva recently announced the launch of an authorized generic version of ACTOplusmet®, used to help improve blood sugar control in adults with type 2 diabetes. Teva Pharmaceutical Industries Limited report is accessible for free by registering today at

Forest Laboratories, along with Almirall, S.A., has also had recent success with the FDA, as the administration approved Tudorza™ Pressair™ for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Forest Laboratories Inc. report is accessible for free by registering today at

The two Drug Manufacturers - Other stocks research reports are available for free by signing up now on the link below.


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information